All of Medytox starts from R&D.

Pipeline

R&D is a starting point of drug development and commercialization and a locomotive in realizing continuous growth.

To keep our pride of R&D-based biopharmaceutical company, Medytox invests more than 15% of the total sales in R&D – Especially with Gwanggyo R&D Center, established with an one-stop system to conduct all drug development processes except for clinical trial, we are developing biopharmaceuticals that will pioneer the global market.
01
Candidate Selection
Securing
competitive technology /
substances
02
Nonclinical Study
Cell& animal
based efficacy
and toxicity test
03
Clinical study
Administration
dose selection &
therapeutic validation
04
Approval
Product Approval
Pipeline
Pipeline
Biodrug
Pipeline
Indications
Candidates Selection
Nonclinical study
Phase I
Phase II
Phase III
Approval
Countries conducting clinical studies
Neuronox®
Post-stroke upper limb spasticity
Korea
Pediatric cerebral palsy foot deformities
Korea
Benign essential blepharospasm
Korea
Glabellar wrinkles
Korea
Glabellar wrinkles
China, Taiwan
Essential blepharospasm
China
Neck dystonia
Korea
Benign masseteric hypertrophy
Korea
Idiopathic overactive bladder
Korea
Lateral canthal wrinkles
Korea
Migraine
Korea
Innotox®
Glabellar wrinkles
Korea
Aesthetic and treatment Licensing out Allergan
USA/Europe
Coretox®
Glabellar wrinkles
Korea
Post-stroke upper limb spasticity
Korea
MT912
Macular degeneration
-
MT914
Diabetic retinopathy
-
MT925
Type 1 diabetes
-
MT927
Immunological disease
-
MT932
Immunological disease
-
MT933
Melanoma
-
MT971
Inflammatory bowel disease
-
MT981
Various solid tumor
-
바이오 의약품 그래프
Medical Device
Pipeline
Indications
Candidates Selection
Nonclinical study
Phase I
Approval
Countries conducting clinical studies
Neuramis®
series *
Facial wrinkles
Korea
Neuramis®
Volume Lidocaine
Midfacial Volume
Korea
 
 
China
Neuramis®
Deep Lidocaine
Nose, lips wrinkles
China
Potenfill®
Penis enlargement
Korea
MT942
Prevention of adhesion
Korea
MT943
Facial wrinkles
Korea
* Neuramis® Light Lidocaine, Neuramis® Lidocaine, Neuramis® Deep, Neuramis® Deep Lidocaine, Neuramis® Volume Lidocaine
Medical Device Graph
Synthetic Drugs
Pipeline
Indications
Candidates Selection
Nonclinical study
Phase I
Phase II
Phase III
Approval
Countries conducting clinical studies
MT921
Fat reduction injection
-
MT941
Osteoarthritis
-
Synthetic Drugs Graph
Health Supplements
Pipeline
Indications
Candidates Selection
Nonclinical study
Phase I
Phase II
Phase III
Approval
Countries conducting clinical studies
MT961
Decreasing body fat
-
MT963
Relieving hangover
-
Health Supplements Graph